CONTE, PIERFRANCO

CONTE, PIERFRANCO  

Mostra records
Risultati 1 - 20 di 590 (tempo di esecuzione: 0.083 secondi).
Titolo Data di pubblicazione Autori Rivista Serie Titolo libro
0.1 grams of sub-cutaneous adipose tissue (SCAT) as source of adult multipotent mesenchymal stromal cells (MSC) for cell-based therapies. 2007 CONTE, PIERFRANCO + BLOOD - -
119P The role of circulating markers in predicting immune-related adverse events (irAEs) and their recurrence in advanced non-small cell lung cancer (aNSCLC) patients (pts) 2021 Dal Maso, A.Ferro, A.Pretelli, G.Frega, S.Menis, J.Pasello, G.Guarneri, V.Conte, P. F.Bonanno, L. + JOURNAL OF THORACIC ONCOLOGY - -
1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI) 2020 Dal Maso, A.Ferro, A.Lorenzi, M.Scattolin, D.Frega, S.Bonanno, L.Indraccolo, S.Calabrese, F.Guarneri, V.Conte, P. F.Pasello, G. + ANNALS OF ONCOLOGY - -
149P First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW) 2021 Lorenzi, M.Dal Maso, A.Ferro, A.Scattolin, D.Indraccolo, S.Frega, S.Menis, J.Bonanno, L.Guarneri, V.Conte, P. F.Pasello, G. + JOURNAL OF THORACIC ONCOLOGY - -
166P: Non-small cell lung cancer (NSCLC) patients with rare or complex epidermal growth factor receptor (EGFR) mutations: A single institution series 2016 Pasello, GFREGA, STEFANOIndraccolo, SFASSAN, MATTEOBonanno, LCONTE, PIERFRANCOCALABRESE, FIORELLA + JOURNAL OF THORACIC ONCOLOGY - -
186O Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized shortHER trial 2018 Maria Vittoria DieciPierfranco ConteValentina Guarneri + ANNALS OF ONCOLOGY - ESMO 2018 Abstract Book (Ann Oncol)
18F-Fluoroestradiol Positron Emission Tomography In Breast Cancer Patients: Systematic Review Of The Literature &; Meta-Analysis 2016 DIECI, MARIA VITTORIAGUARNERI, VALENTINACONTE, PIERFRANCO + CURRENT RADIOPHARMACEUTICALS - -
211P: Inflammatory cells characterization and localization in malignant pleural mesothelioma (MPM) tissue samples: Correlation with histologic subtype and prognosis 2016 Urso, LBonanno, LLunardi, FVuljan, S. EConte, P. FREA, FEDERICOCALABRESE, FIORELLA + JOURNAL OF THORACIC ONCOLOGY - -
28P Different genetic profiling in lung adenocarcinoma of smokers with and without chronic obstructive pulmonary disease (COPD): An exploratory analysis by next generation sequencing (NGS) 2016 Bonanno, L.SCHIAVON, MARCOLUNARDI, FRANCESCAPASELLO, GIULIACONTE, PIERFRANCOREA, FEDERICOINDRACCOLO, STEFANOCALABRESE, FIORELLA + JOURNAL OF THORACIC ONCOLOGY - -
4-Demethoxydaunorubicin (IMI-30) in refractory epithelial ovarian cancer: a pilot study. 1987 CONTE, PIERFRANCO + CHEMIOTERAPIA - -
5-fluorouracil administered as a 48-hour semi-intermittent infusion in combination with leucovorin, cisplatin and epirubicin: phase II study in advanced gastric cancer patients 2004 CONTE, PIERFRANCO + AMERICAN JOURNAL OF CLINICAL ONCOLOGY: CANCER CLINICAL TRIALS - -
5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial 2016 Michelotti, AndreaPastorino, SimonaConte, PierFranco + BREAST CANCER RESEARCH AND TREATMENT - -
5-Fluoruracil administered as a 48-hours chronomodulated infusion in combination with Leucovorin and Cisplatin: a randomized phase II study in metastatic colorectal cancer. 2001 CONTE, PIERFRANCO + ONCOLOGY - -
51P Liver kinase B1 (LKB1) and phosphorylated AMP kinase (AMPK) expression in small cell lung cancer (SCLC): Association with prognosis and tumour immune microenvironment (TIME) features 2021 Bonanno, L.Dal Maso, A.Zulato, E.Fassan, M.Pasello, G.Guarneri, V.Calabrese, F.Rea, F.Indraccolo, S.Conte, P. F. + JOURNAL OF THORACIC ONCOLOGY - -
77P Glycolytic marker monocarboxylate transporter 4 (MCT4) and outcome to bevacizumab (bev): An exploratory analysis in advanced non-small cell lung cancer (A-NSCLC) 2016 Bonanno, LCALABRESE, FIORELLAPasello, GConte, P. F + JOURNAL OF THORACIC ONCOLOGY - -
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study 2018 Conte, PGuarneri, V + ANNALS OF ONCOLOGY - -
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. 2010 Guarneri VCONTE, PIERFRANCO + CANCER RESEARCH - -
[Adjuvant chemotherapy in breast cancer. International perspective] 2000 Conte, P F + TUMORI - -
[Experimentation with Di Bella polychemotherapy in Tuscany]. 2000 CONTE, PIERFRANCO + EPIDEMIOLOGIA E PREVENZIONE - -
[Targeted therapy in non-small cell lung tumors: recent findings and future perspectives] 2005 Conte, P F + PATHOLOGICA - -